Learn more Cytokinetics (CYTK) said Thursday that the United Kingdom's Medicines and Healthcare products Regulatory Agency has granted aficamten marketing authorisation across the UK for the treatment ...

The FDA granted Fast Track designation to HTX-001, an investigational lncRNA-targeting antisense therapy for nonobstructive hypertrophic cardiomyopathy.

Authorisation from MRHA and Recommendation from NICEThis announcement is intended for business and financial media and investors only SOUTH SAN ...

Learn more Lexicon Pharmaceuticals (LXRX) has completed patient enrollment and randomization in a pivotal phase 3 trial of sotagliflozin in patients with symptomatic obstructive and non-obstructive ...

Tafamidis Accord, a generic of Vyndaqel, could widen treatment availability for adults with hereditary transthyretin amyloidosis with cardiomyopathy.

Cytokinetics is one of the first drugmakers to benefit from the UK's dual regulatory and reimbursement appraisals, getting a ...

Novel mavacamten had a big impact on quality of life in obstructive hypertrophic cardiomyopathy, according to a secondary analysis of the EXPLORER-HCM trial. The cardiac myosin inhibitor improved ...

In a move greatly welcomed by heart charities, the National Institute for Health and Care Excellence (NICE) has approved mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy ...

At a contentious meeting with possible implications for other rare disease drugmakers, outside experts ultimately determined ...

Study substantially exceeded enrollment target of 500 patientsTopline results anticipated in Q1 2027THE WOODLANDS, Texas, July 27, 2026 (GLOBE ...

Cardiomyopathy weakens, enlarges, or stiffens the heart muscle. Heart failure is when the heart is unable to pump enough blood around the body, resulting in symptoms. Cardiomyopathy is one of the ...